• 1
    Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322:15611566.
  • 2
    Shigemitsu Y, Hamada M, Mukai M, et al. Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens. 1995;13:155160.
  • 3
    Shigematsu Y, Hamada M, Ohtsuka T, et al. Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Am J Hypertens. 1998;11:11711177.
  • 4
    Cuspidi C, Macca G, Michev I, et al. Left ventricular concentric remodeling and extracardiac target organ damage in essential hypertension. J Hum Hypertens. 2002;16:385390.
  • 5
    Esquitin R, Razzouk L, Peterson GE, et al. Left ventricular hypertrophy by electrocardiography and echocardiography in the African American Study of Kidney Disease Cohort Study. J Am Soc Hypertens. 2012;6:193200.
  • 6
    Levy D, Labib SB, Anderson KM, et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81:815820.
  • 7
    Ogah OS, Adebanjo AT, Otukoya AS, Jagusa TJ. Echocardiography in Nigeria: use, problems, reproducibility and potentials. Cardiovas Ultrasound. 2006;4:13k.
  • 8
    O'Neil L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans. 2000;28:557563.
  • 9
    Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):21862190.
  • 10
    Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 response. J Exp Med. 2000;191:10691076.
  • 11
    Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham heart study. Clin Chem. 2012;58:16731681.
  • 12
    Rickham PP. Declaration of Helsinki. Br Med J. 1964;ii:177.
  • 13
    HM K. Outcomes research in the global environment: learning from each other. Circ Cardiovasc Qual Outcomes. 2011;4:489490.
  • 14
    The Seventh Report of the Joint of the Joint National Committee on Prevention, Evaluation and Treatment of High Blood Pressure. U.S Department of Health and Human Services. NIH Publication August 2004;No 04-5230
  • 15
    Dieplinger B, Januzzi J, Steinmair M, et al. Analytical and clinical evaluation of novel high sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chem Acta. 2009;409:3340.
  • 16
    Dieplinger B, Egger M, Poelz W, et al. Long-term stability of soluble ST2 in frozen plasma samples. Clin Biochem. 2010;43:11691170.
  • 17
    Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752756.
  • 18
    Prickett TC, Yandle TG, Nicholls MG, et al. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun. 2001;286(3):513517.
  • 19
    Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization and comparison to other methods. Hypertension. 1987;9:11191126.
  • 20
    Ota T, Kisslo J, von Ramm OT, Yoshikawa J. Real-time, volumetric echocardiography: usefulness of volumetric scanning for the assessment of cardiac volume and function. J Cardiol. 2001;37(Suppl 1):93101.
  • 21
    Park SH, Shub C, Nobrega TP, et al. Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr. 1996;9:119128.
  • 22
    Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation. 2001;104:12481254.
  • 23
    Kolo PM, Omotosho ABO, Katibi IA, et al. Gender differences in left ventricular size and geometric patterns of hypertension subjects. Cardiology. 2008;4:1115.
  • 24
    Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovasc Disorders. 2008;22:16.
  • 25
    Weir RAP, Miller AM, Murphy GEJ, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after myocardial infarction. JACC. 2010;55:243250.
  • 26
    Takeda T, Kohno M. Brain natriuretic peptide in hypertension. Hypertens Res. 1995;18:259266.
  • 27
    Toda K, Sato Y, Hara T, et al. Correlates of NT-Pro BNP concentration in patients with essential hypertension in absence of congestive heart failure. J Clin Lab Anal. 2010;24(1):1216.